Compositions and Methods for the Treatment of Norovirus Infection
AssigneesAlios BioPharma, Inc., Indiana University Research and Technology Corporation
InventorsCh. V. Subba-Reddy, C. Cheng Kao, Dave Smith, Leo Beigelman
Life of this patent
Estimating the term…
Abstract
Compositions and methods for the treatment of norovirus infection are disclosed.
Claims14
A method for the treatment of norovirus infection associated with clinical pathology in a patient in need thereof comprising administration of an effective amount of VX-222 or a pharmaceutical salt or prodrug thereof, said VX-222 being effective to inhibit norovirus RNA polymerase activity.
A viral RNA polymerase inhibitor for the treatment of norovirus infection having the
- wherein:
- X1 and X2 are independently C, NH, O, or S;
- R1 is a lower alkyl, alkyl, cycloalkyl, or aryl;
- R2 is a lower alkyl, alkyl, cycloalkyl, or aryl;
- R3 is a lower alkyl, H, or ═O;
- R4 is a lower alkyl, alkyl, cycloakyl, or aryl;
- and
- R5 is a lower alkyl, alkyl, cycloakyl, or aryl.
A method for identifying agents which modulate norovirus RNA polymerase activity associated with clinical pathology comprising:
- a) incubating cells expressing said viral RNA polymerase and at least one innate immune receptor and a reporter gene operably linked to an interferon beta promoter in the presence and absence of a test agent, wherein in synthesis of viral RNA from said RNA polymerase triggers a cellular defense response which is effective to activate expression of said reporter gene;
- and
- b) measuring reporter gene expression in the presence and absence of said agent, alterations of said reporter gene expression in the presence of said agent being indicative of RNA polymerase modulatory activity.
Dependencies are inferred from the claim text.